Paper Details

  1. Home
  2. Paper Details

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.

Author: BelloNatalia, BurmesterGerd R, DeberdtWalter, DurezPatrick, IssaMaher, SmolenJosef S, TakeuchiTsutomu, TaylorPeter C, TerresJorge Ross, WinthropKevin L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the long-term safety of baricitinib, an oral selective Janus kinase inhibitor, in patients with active rheumatoid arthritis. The study analyzed data from an integrated database of 3770 patients who received baricitinib for up to 9.3 years. The results showed that baricitinib maintained a similar safety profile to earlier analyses, with no new safety signals identified.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To report long-term safety from the completed extension trial of baricitinib, an oral selective Janus kinase inhibitor, in patients with active rheumatoid arthritis (RA). METHODS: Treatment-emergent adverse events are summarised from an integrated database (9 phase III/II/Ib and 1 long-t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862028/

データ提供：米国国立医学図書館（NLM）

Baricitinib: A Long-Term Look at Safety in Rheumatoid Arthritis Treatment

The desert of rheumatoid arthritis (RA) is a challenging landscape, where researchers seek to find safe and effective treatments for this chronic inflammatory disease. This study examines the long-term safety of baricitinib, an oral Janus kinase inhibitor, in patients with active RA, following a median of 4.6 years of treatment. The researchers, like experienced camel caravan guides, meticulously track the safety profile of baricitinib, ensuring its long-term efficacy and minimizing potential risks. This study provides valuable insights into the long-term safety of baricitinib, offering reassurance for patients and clinicians alike.

A Beacon of Safety: Long-Term Data on Baricitinib

The study's findings, like a reassuring oasis in the desert of RA treatment, demonstrate the long-term safety and efficacy of baricitinib. This research, like a dependable guidepost in the vast landscape of RA treatment, offers valuable information for patients and healthcare providers, ensuring that baricitinib can be used safely and effectively over an extended period.

Navigating the Desert of RA Treatment: A Journey Towards a Healthier Future

This study highlights the importance of long-term safety data in the development and use of medications. The findings offer reassurance for patients and clinicians, confirming the safety and efficacy of baricitinib over an extended period. This research contributes to the ongoing quest for effective and safe treatments for RA, paving the way for a healthier future for those living with this chronic condition.

Dr. Camel's Conclusion

This study underscores the long-term safety and efficacy of baricitinib in treating RA, offering a valuable resource for patients and clinicians. The findings highlight the importance of long-term safety data in evaluating medications, ensuring their continued effectiveness and minimizing potential risks. This research serves as a guidepost in the ongoing quest for safe and effective treatments for RA, paving the way for a healthier future for those living with this chronic condition.

Date :
  1. Date Completed 2022-03-15
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

34706874

DOI: Digital Object Identifier

PMC8862028

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.